Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
about
Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarkersiRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survivalA signaling network in phenylephrine-induced benign prostatic hyperplasia.Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.
P2860
Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
@ast
Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
@en
type
label
Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
@ast
Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
@en
prefLabel
Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
@ast
Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
@en
P1476
Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide
@en
P2093
Gerd Schmitz
P304
P577
2006-12-01T00:00:00Z